All In Biotech

Drug Trial Radar · NCT05248659

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy.

Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

600

Planned (sponsor's estimate)

Start

Apr 5, 2022

Primary completion

Dec 28, 2028

Study completion Dec 31, 2029

Sponsor

Sponsor type
Industry
First posted
Feb 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN

Conditions

  • Immunoglobulin A Nephropathy

Interventions

  • Sibeprenlimab 400 mg s.c. Q4weeksDrug

    Sibeprenlimab 400 mg s.c. q 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: From baseline to the end-of-trial visit in Week 112.

Locations

158 sites in 31 countries. Site status is shown where the registry gives one.

  • Clinical Research Site #336

    Birmingham, Alabama

  • Clinical Research Site #325

    Los Angeles, California

  • Clinical Research Site #370

    Palo Alto, California

  • Clinical Research Site #330

    Denver, Colorado

  • Clinical Research Site #323

    Lauderdale Lakes, Florida

  • Clinical Research Site #373

    Atlanta, Georgia

  • Clinical Research Site #356

    Lawrenceville, Georgia

  • Clinical Research Site #369

    Boston, Massachusetts

  • Clinical Research Site #331

    Worcester, Massachusetts

  • Clinical Research Site #320

    Shelby, Michigan

  • Clinical Research Site #346

    Great Neck, New York

  • Clinical Research Site #350

    Columbus, Ohio

  • Clinical Research Site #374

    Dakota Dunes, South Dakota

  • Clinical Research Site #324

    Houston, Texas

  • Clinical Research Site #361

    Milwaukee, Wisconsin

  • Clinical Research Site #800

    Buenos Aires, Argentina

  • Clinical Research Site #802

    Buenos Aires, Argentina

  • Clinical Research Site #801

    Córdoba, Argentina

  • Clinical Research Site #011

    Liverpool, Australia

  • Clinical Research Site #003

    Garran, Australian Capital Territory, Australia

  • Clinical Research Site #013

    Concord, New South Wales, Australia

  • Clinical Research Site #014

    Kogarah, New South Wales, Australia

  • Clinical Research Site

    New Lambton Heights, New South Wales, Australia

  • Clinical Research Site #006

    Saint Leonards, New South Wales, Australia

  • Clinical Research Site #012

    Adelaide, South Australia, Australia

  • Clinical Research Site #001

    Fitzroy, Victoria, Australia

  • Clinical Research Site #010

    St Albans, Victoria, Australia

  • Clinical Research Site #401

    Genk, Belgium

  • Clinical Research Site #405

    Genk, Belgium

  • Clinical Research Site #831

    Rio de Janeiro, Brazil

  • Clinical Research Site #823

    São Paulo, Brazil

  • Clinical Research Site #820

    Recife, Pernambuco, Brazil

  • Clinical Research Site #824

    Porto Alegre, Rio Grande do Sul, Brazil

  • Clinical Research Site #821

    Joinville, Santa Catarina, Brazil

  • Clinical Research Site #822

    São José do Rio Preto, So Paulo, Brazil

  • Clinical Research Site #300

    Calgary, Alberta, Canada

  • Clinical Research Site #305

    Scarborough Village, Ontario, Canada

  • CISSS de la Monteregie centre-Centre de recherche Hopital Charles Lemoyne

    Greenfield Park, Quebec, Canada

  • Clinical Research Site #036

    Beijing, Beijing Municipality, China

  • Clinical Research Site #020

    Beijing, Beijing Municipality, China

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.